Work Here?
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series F
Total Funding
$272.1M
Headquarters
Boston, Massachusetts
Founded
2014
Emulate Bio develops Organ-on-a-Chip technology that simulates human biology more accurately than traditional models. This technology helps researchers and pharmaceutical companies improve the success rate of clinical trials and enhance patient safety. Their platform includes instruments, consumables, and software, allowing users to better understand human biology and develop safer drugs. Emulate Bio differentiates itself by providing a flexible, user-friendly system and generating revenue through product sales and research publications. The company's goal is to enhance human health and save lives by improving drug development processes.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$272.1M
Above
Industry Average
Funded Over
8 Rounds
Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, announced the release of its new Chip-R1(TM) Rigid Chip, designed to minimize drug absorption and enhance biological modeling.
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication of a landmark study, âPerformance assessment and economic analysis of a human Liver-Chip for predictive toxicology,â in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which researchers compared the performance of human Liver-Chips in predicting drug-induced liver injury (DILI) to those of animal in vivo modelsâthe current industry standardâand primary human 3D hepatic spheroids. In addition to assessing and quantifying model performance, this study effectively qualifies the Emulate human Liver-Chip model against the guidelines defined by IQ MPS, an affiliate of the International Consortium for Innovation and Quality in Pharmaceutical Development. âThis first-of-its-kind study demonstrates the Emulate human Liver-Chip can better predict drug safety than other methods for modeling liver toxicity,â said Jim Corbett, Chief Executive Officer of Emulate. "In light of these findings, the pharmaceutical industry and government agencies have a responsibility to both patients and researchers to bring efficient, accurate, and safe preclinical testing modelsâlike Organ-Chipsâinto the drug development process.â
BOSTON--(BUSINESS WIRE)--Emulate, Inc., a leading provider of next-generation in vitro models, today announced the launch of its new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks, not months, as with animal models. This technology allows them to rapidly iterate on AAV design to optimize delivery of gene therapies and accelerate development. âThe ability to more rapidly optimize AAV design using this application is a game-changer for the gene therapy industry,â said Emulate CEO Jim Corbett. âWe are excited to offer this novel application to researchers in biopharmaceutical, academic, and government entities around the world who are exploring gene therapy as a potential to treat a wide range of diseases such as cancer, cystic fibrosis, heart disease, diabetes, and metabolic disease.â
(Emulate) Organ-on-a-chip maker Emulate has launched an upgraded offering for researchers studying inflammatory bowel disease with its tissue model that helps illustrate how immune cells are activated and circulate through the body.
Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company âs prestigious annual list of the Worldâs Most Innovative Companies for 2022.
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series F
Total Funding
$272.1M
Headquarters
Boston, Massachusetts
Founded
2014
Find jobs on Simplify and start your career today